STARD4 and hepatocellular carcinoma: Additionally, overexpression of STARD4 made the HCC cells more resistant to lenvatinib and induced lower growth inhibition in PLC/PRF/5 and SMMC 7721 cells, with a significant increase in IC50 of lenvatinib (Fig. 6B).